ANVS

Annovis Bio, Inc. develops therapies for neurodegenerative diseases, specifically targeting Alzheimer’s disease and Parkinson’s disease. The company focuses on halting the death of nerve cells through its lead compound, buntanetap, which aims to reduce neurotoxic proteins. Annovis operates in the biotechnology sector, conducting clinical trials and research to advance its drug development programs. Its activities include regulatory interactions and compliance to ensure the successful progression of its therapies.